![Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/cae3bb1d-3b59-4765-b8cf-cd18eb28a9b9/bjh12384-fig-0003-m.jpg)
Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library
![PDF) A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells PDF) A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells](https://www.researchgate.net/publication/338086934/figure/fig4/AS:838355818405889@1576891011949/17f-inhibits-STAT5B-N642H-activity-and-expression-in-Ba-F3-cells-A-Cells-were-treated_Q320.jpg)
PDF) A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells
![PDF) The transcriptional repressor Bcl6 promotes pre-TCR induced differentiation to CD4+CD8+ thymocyte and attenuates Notch1 activation PDF) The transcriptional repressor Bcl6 promotes pre-TCR induced differentiation to CD4+CD8+ thymocyte and attenuates Notch1 activation](https://i1.rgstatic.net/publication/344222157_The_transcriptional_repressor_Bcl6_promotes_pre-TCR_induced_differentiation_to_CD4CD8_thymocyte_and_attenuates_Notch1_activation/links/5f6a53f7458515b7cf46d55e/largepreview.png)
PDF) The transcriptional repressor Bcl6 promotes pre-TCR induced differentiation to CD4+CD8+ thymocyte and attenuates Notch1 activation
![Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/5a636b6e-588f-4e0b-befe-b0554820b177/bjh.2013.162.issue-3.cover.jpg)
Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library
![PDF) Presence of Lamin A is Required for GATA3 and ERα Downregulation by Histone Deacetylase Inhibitor in Breast Cancer Cells PDF) Presence of Lamin A is Required for GATA3 and ERα Downregulation by Histone Deacetylase Inhibitor in Breast Cancer Cells](https://i1.rgstatic.net/publication/326786450_Presence_of_Lamin_A_is_Required_for_GATA3_and_ERa_Downregulation_by_Histone_Deacetylase_Inhibitor_in_Breast_Cancer_Cells/links/5b638612a6fdcc45b30c6a4e/largepreview.png)
PDF) Presence of Lamin A is Required for GATA3 and ERα Downregulation by Histone Deacetylase Inhibitor in Breast Cancer Cells
![PDF) Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2 PDF) Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2](https://i1.rgstatic.net/publication/259770843_Targeting_STAT5_in_Hematologic_Malignancies_through_Inhibition_of_the_Bromodomain_and_Extra-Terminal_BET_Bromodomain_Protein_BRD2/links/5422d4590cf290c9e3ad626d/largepreview.png)
PDF) Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2
Development and Characterization of Tool Compounds Targeting the Runt Domain╎s interaction With Cbfβ
![PDF) MEF2B mutations lead to deregulated expression of the BCL6 oncogene in Diffuse Large B cell Lymphoma PDF) MEF2B mutations lead to deregulated expression of the BCL6 oncogene in Diffuse Large B cell Lymphoma](https://i1.rgstatic.net/publication/256100894_MEF2B_mutations_lead_to_deregulated_expression_of_the_BCL6_oncogene_in_Diffuse_Large_B_cell_Lymphoma/links/0deec53c530523cce0000000/largepreview.png)
PDF) MEF2B mutations lead to deregulated expression of the BCL6 oncogene in Diffuse Large B cell Lymphoma
![Lyuba VARTICOVSKI | Staff | National Cancer Institute (USA), Bethesda | NCI | Center for Cancer Research Lyuba VARTICOVSKI | Staff | National Cancer Institute (USA), Bethesda | NCI | Center for Cancer Research](https://www.researchgate.net/profile/Luke-Iwanowicz/publication/233889457/figure/fig4/AS:278902770552861@1443507010806/Analysis-of-water-samples-for-glucocorticoid-and-androgen-contamination-a-Schematic_Q320.jpg)
Lyuba VARTICOVSKI | Staff | National Cancer Institute (USA), Bethesda | NCI | Center for Cancer Research
![Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/4f5b7e28-6c4c-4bb6-95af-053ea2c836bf/bjh12384-fig-0002-m.jpg)
Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library
![PDF) Presence of Lamin A is Required for GATA3 and ERα Downregulation by Histone Deacetylase Inhibitor in Breast Cancer Cells PDF) Presence of Lamin A is Required for GATA3 and ERα Downregulation by Histone Deacetylase Inhibitor in Breast Cancer Cells](https://www.researchgate.net/profile/Callinice-Capo-Chichi/publication/326786450/figure/fig1/AS:655308154208256@1533249047654/SBHA-induces-the-expression-of-endogenous-lamin-A-in-T47D-and-in-MCF7-transfected_Q320.jpg)
PDF) Presence of Lamin A is Required for GATA3 and ERα Downregulation by Histone Deacetylase Inhibitor in Breast Cancer Cells
![Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/93b7f207-7254-442b-9714-6dfdd667e4ac/bjh12384-fig-0001-m.jpg)